At 4.5% CAGR, the Asia Pacific Cardiopulmonary Oxygenator Market is projected to be worth US$ 214.77 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific cardiopulmonary oxygenator market was valued at US$ 164.51 million in 2022 and is expected to reach US$ 214.77 million by 2028, registering a CAGR of 4.5% from 2022 to 2028. Increasing usage of cardiopulmonary oxygenators in pediatric and neonatal patients and use of portable extracorporeal membrane oxygenation in lung transplant procedures are the critical factors attributed to the Asia Pacific cardiopulmonary oxygenator market expansion.                    

Congenital heart defects are among the most common birth defects affecting populations worldwide. Pediatric membrane oxygenator devices have been developed with efforts made over a long period to assist in the treatment of these defects. After cardiac surgical procedures, numerous pediatric patients have experienced improved clinical outcomes in the quality of life and survival rate. For achieving this, pediatric membrane oxygenators are used in conjunction with the heart–lung machine, which assists in the repair of most congenital cardiac defects. Thus, oxygenators have become an important part of modern pediatric cardiac surgical setting that supports whole-body perfusion.

 Further, Lilliput is a range of open-system oxygenators offered by the company for supporting pediatric patients during cardiac pulmonary bypass.

With continued research and development and the introduction of extracorporeal membrane oxygenation (ECMO) devices, companies in the cardiopulmonary oxygenator market have managed to address complications regarding the incidence of air embolism, hemolysis, blood-to-water interface reactions, and other adverse events. In November 2022, Fresenius Medical Care’s heart & lung division—Xenios AG—introduced the MiniLung petite kit, which is specially designed for neonatal and pediatric ECMO. The kit is meant to offer respiratory or cardiopulmonary life support by enabling extracorporeal circulation and physiological gas exchange in the blood.

The ECMO treatment can help save the lives of critically ill patients, especially newborns, infants, or children suffering from severe cardiopulmonary diseases. Thus, the research and development for improvements in ECMO provide opportunities for companies in the cardiopulmonary oxygenator market.

On the contrary, lack of skilled professionals hurdles the growth of Asia Pacific cardiopulmonary oxygenator market

Based on product, the Asia Pacific cardiopulmonary oxygenator market is bifurcated into membrane oxygenator and bubble oxygenator. The membrane oxygenator segment held 91.8% market share in 2022, amassing US$ 151.06 million. It is projected to garner US$ 199.30 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on application, the Asia Pacific cardiopulmonary oxygenator market is bifurcated into cardiac and respiratory. The cardiac segment held 67.9% market share in 2022, amassing US$ 111.63 million. It is projected to garner US$ 151.26 million by 2028 to expand at 5.2% CAGR during 2022–2028. Further, cardiac is segmented into acute myocardial infarction, myocarditis, post-transplant complications, decompensated cardiomyopathy, and others. Further, respiratory is segmented into respiratory failure, acute respiratory distress syndrome, pulmonary embolism, pneumonia, and COVID-19.

Based on type, the Asia Pacific cardiopulmonary oxygenator market is bifurcated into reusable cardiopulmonary oxygenators and disposable cardiopulmonary oxygenators. The reusable cardiopulmonary oxygenators segment held 91.6% market share in 2022, amassing US$ 150.62 million. It is projected to garner US$ 198.37 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on Age Group, the Asia Pacific cardiopulmonary oxygenator market is segmented into adults, pediatric, and neonates. The adults segment held 72.0% market share in 2022, amassing US$ 118.50 million. It is projected to garner US$ 156.19 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on end use, the Asia Pacific cardiopulmonary oxygenator market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment held 79.5% share in Asia Pacific cardiopulmonary oxygenator market in 2022, amassing US$ 130.79 million. It is projected to garner US$ 171.52 million by 2028 to expand at 4.6% CAGR during 2022–2028.

Based on country, the Asia Pacific cardiopulmonary oxygenator market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of  Asia Pacific.  Our regional analysis states that China captured 30.1% market share in 2022. It was assessed at US$ 49.50 million in 2022 and is likely to hit US$ 66.02 million by 2028, exhibiting a CAGR of 4.9% during the forecast period.     

Key players dominating the Asia Pacific cardiopulmonary oxygenator market are Getinge AB; LivaNova Plc; Medtronic Plc; Terumo Corp; Eurosets SRL; Nipro Medical Corp; Microport Scientific Corp; Chalice Medical Ltd; and Fresenius Medical Care AG & Co KGaA among others.   

• In March 2021, Medtronic recalls oxygenator used for cardiopulmonary bypass among kids
• In Sept 2020, Notice of Establishment of Overseas Offices in China.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com